Medical researchers at the University of Alberta have discovered a drug intended for diabetes appears to restore memory in Alzheimer's brain cells.
Jack Jhamandas, a researcher with the Faculty of Medicine & Dentistry at the U of A, is the principal investigator with the team whose research results were recently published in the peer-reviewed publication The Journal of Neuroscience. He works in the Division of Neurology.
The team took brain tissue from animal models with Alzheimer's disease and tested the tissue in the lab, looking specifically at the cells' memory capacity. When brain cells are shocked by a barrage of electrical impulses, the cells "remember" the experience and this is a typical way to test or measure memory in the lab setting.
Amyloid protein, which is found in abnormally large amounts in the memory and cognition parts of the brains of Alzheimer's patients, diminishes memory. A sister protein, known as amylin, which comes from the pancreas of diabetic patients, has the same impact on memory cells.
Jhamandas and his team demonstrated last year that a diabetes drug that never made it to market, known as AC253, could block the toxic effects of amyloid protein that lead to brain cell death.
In the lab, Jhamandas and his teammates, which included Ryoichi Kimura, a visiting scientist from Japan, tested the memory of normal brain cells and those with Alzheimer's—both from animal models. When the drug AC253 was given to brain cells with Alzheimer's and the shock memory tests were redone, memory was restored to levels similar to those in normal cells.
"This is very important because it tells us that drugs like this might be able to restore memory, even after Alzheimer's disease may have set in," says Jhamandas.
His team is continuing their research in this area and wants to see if the drug, when given before symptoms appear, can "stop the impairment of behaviour and cognition altogether in animals destined to develop Alzheimer's," says Jhamandas. Their continued research tests will take a least a year to complete.
He noted it is difficult for AC253 to cross the brain barrier, so research teams in pharmaceutical companies would need to design a similar drug that is easier to penetrate brain cells. Jhamandas says if the tests are successful, he thinks clinical trials could start within about five years, but he stressed that further testing needs to be done before such trials can occur.
"I think what we discovered may be part of the solution, but I can't say it will be the solution. There is a long list of drugs and approaches that haven't panned out as expected in the fight against Alzheimer's. I don't think one drug or approach will solve Alzheimer's disease because it's a complicated disease, but I am cautiously optimistic about our discovery and its implications."
The Canadian Institutes of Health Research funded the work of Jhamandas and his team.
"An estimated 1,125,000 Canadians will be diagnosed with Alzheimer's over the coming 30 years," said Yves Joanette, Scientific Director of the CIHR Institute of Aging. "To respond to this growing health care challenge, CIHR developed the International Collaborative Research Strategy for Alzheimer's Disease. The strategy aims to give Canadians rapid access to the latest approaches to preventing, diagnosing and treating Alzheimer's Disease and related dementias. The findings by Dr. Jhamandas could eventually help reduce the personal, social and economic impacts for Alzheimer's Disease."
University of Alberta Faculty of Medicine & Dentistry: http://www.med.ualberta.ca
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
After a severe brain injury, some people remain in a vegetative or minimally conscious state, unable to speak or move intentionally, and apparently unaware of the world around them. But in recent years, neuroscientists have found signs that some of these patients may still be conscious, at least to a degree. Now researchers have used a branch of mathematics called graph theory to search for neural signatures of consciousness.
Few parasitoids are more bizarre or disturbing than the wasps of the genus Glyptapanteles, whose females inject their eggs into living caterpillars. Once inside, the larvae mature, feeding on the caterpillar’s body fluids before gnawing through its skin en masse and emerging into the light of day. And despite the trauma, not only does the caterpillar survive---initially at least---but the larvae proceed to mind-control it, turning their host into a bodyguard that protects them as they spin their cocoons and finish maturing. Then, finally, the caterpillar starves to death, but only after the tiny wasps emerge from their cocoons and fly away.
From their new book A History of Life in 100 Fossils, Paul Taylor and Aaron O'Dea share the story of 10 incredible fossils
We love origin stories. When we see successful groups of animals and plants, we wonder where they came …
First research of its kind shows that tasers could impair a person's memory and thought process
Sometimes the most fascinating animals are the ones that are no longer with us. The oddly named sthenurine is no exception.
Australian banded stilts use mysterious cues to know when to head toward ephemeral lakes in the country’s otherwise dry interior
The intriguing story of how whale evolution was unpicked is told in The Walking Whales, revealing what it's like to be a globe-trotting palaeontologist
Cells derived from embryos appear to have improved vision in more than half of the 18 patients who had become legally blind because of two progressive, currently incurable eye diseases.
Oil rigs are rarely lauded by conservationists, but fish seem to love them – they have more fish living around them than natural rocky reefs do